United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 30th Annual Healthcare Conference.
The session will take place virtually on Monday, November 8, 2021, from 8:50 a.m. to 9:30 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.
United Therapeutics: Enabling Inspiration
We build on the strength of our research and development expertise and distinctive, entrepreneurial culture that encourages diversity, innovation, creativity, sustainability, and, simply, fun. Since its inception, our mission has been to find a cure for pulmonary arterial hypertension and other life-threatening diseases. Toward this goal we have successfully gained FDA approval for five medicines, we are always conducting new clinical trials, and we are working to create an unlimited supply of manufactured organs for transplantation.
We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-sensitive energy utilization.
You can learn more about what it means to be a PBC here: unither.com/PBC.
